Справка
x
Поиск
Закладки
Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Уротелиальный рак верхних мочевыводящих путей
Список литературы
Поставить закладку
Siegel R.L. et al. Cancer statistics 2015. CA Cancer J Clin 2015;65:5.
Soria F. et al. Epidemiology diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017;35:379.
Margulis V. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115:1224.
Shariat S.F. et al. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 2011;29:481.
Roupret M. et al. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (Lynch syndrome) tumor spectrum. Eur Urol 2008;54:1226.
Acher P. et al. Towards a rational strategy for the surveillance of patients with Lynch syndrome (hereditary non-polyposis colon cancer) for upper tract transitional cell carcinoma. BJU Int 2010;106:300.
Matin S.F. et al. Misclassification of Upper Tract Urothelial Carcinoma in Patients with Lynch Syndrome. JAMA Oncol 2018;4:1010.
Therkildsen C. et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Mol Oncol 2018;12:1286.
Colin P. et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int 2009;104:1436.
Crivelli J.J. et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2014;65:742.
Cosyns J.P. Aristolochic acid and “Chinese herbs nephropathy”: a review of the evidence to date. Drug Saf 2003;26:33.
Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013;54:1.
Rosenquist T.A. et al. Mutational signature of aristolochic acid: Clue to the recognition of a global disease. DNA Repair (Amst) 2016;44:205.
Jelakovic B. et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 2012;81:559.
Chen C.H. et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci U S A 2012;109:8241.
Nortier J.L. et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 2000;342:1686.
Grollman A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ Mol Mutagen 2013;54:1.
Babjuk M. et al. EAU guidelines on non-muscle-invasive bladder cancer (T1, T1 and CIS). In: EAU guidelines, presented at the 34th EAU Annual Congress. Barcelona: EAU Guidelines Office, 2019.
Siegel R.L. et al. Cancer statistics, 2017. CA Cancer J Clin 2017;66:7.
Munoz J.J. et al. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000;164:1523.
Cosentino M. et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol 2013;31:141.
Xylinas E. et al. Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. Eur Urol 2012;61:1069.
Li W.M. et al. Oncologic outcomes following three different approaches to the distal ureter and bladder cuff in nephroureterectomy for primary upper urinary tract urothelial carcinoma. Eur Urol 2010;57:963.
Inman B.A., et al. Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality. Cancer 2009;115:2853.
Cowan N.C. CT urography for hematuria. Nat Rev Urol 2012;9:218.
Ito Y. et al. Preoperative hydronephrosis grade independently predicts worse pathological outcomes in patients undergoing nephroureterectomy for upper tract urothelial carcinoma. J Urol 2011;185:1621.
Raman J.D. et al. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? Urol Oncol 2011; 29:716.
Reynolds J.P. et al. Comparison of urine cytology and fluorescence in situ hybridization in upper urothelial tract samples. Cancer Cytopathol 2014;122:459.
Hurel S. et al. Influence of preoperative factors on the oncologic outcome for upper urinary tract urothelial carcinoma after radical nephroureterectomy. World J Urol 2015;33:335.
Verhoest G. et al. Predictive factors of recurrence and survival of upper tract urothelial carcinomas. World J Urol 2011;29:495.
Takahashi N. et al. Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J Urol 2010;183:1330.
Walton T.J. et al. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. BJU Int 2011;108:406.
Marchioni M. et al. Impact of diagnostic ureteroscopy on intravesical recurrence in patients undergoing radical nephroureterectomy for upper tract urothelial cancer: a systematic review and meta-analysis. BJU Int 2017;120:313.
Guo R.Q. et al. Impact of ureteroscopy before radical nephroureterectomy for upper tract urothelial carcinomas on oncological outcomes: a meta-analysis. BJU Int 2018;121:184.
Bus M.T. et al. Optical diagnostics for upper urinary tract urothelial cancer: technology, thresholds, and clinical applications. J Endourol 2015;29:113.
Brien J.C. et al. Preoperative hydronephrosis, ureteroscopic biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. J Urol 2010;184:69.
Abouassaly R. et al. Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology 2010;76:895.
Kata S.G. et al. Photodynamic diagnostic ureterorenoscopy: A valuable tool in the detection of upper urinary tract tumour. Photodiagnosis Photodyn Ther 2016;13:255.
Matsumoto K. et al. Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2011;108:E304.
Singla N. et al. A multi-institutional comparison of clinicopathological characteristics and oncologic outcomes of upper tract urothelial carcinoma in China and the United States. J Urol 2017;197:1208.
Fajkovic H. et al. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. J Urol 2012;187:845.
Roscigno M. et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60:776.
Lughezzani G. et al. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. Urology 2010;75:118.
Simsir A. et al. Prognostic factors for upper urinary tract urothelial carcinomas: stage, grade, and smoking status. Int Urol Nephrol 2011;43:1039.
Rink M. et al. Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. Eur Urol 2013;63:1082.
Sundi D. et al. Upper tract urothelial carcinoma: impact of time to surgery. Urol Oncol 2012;30:266.
Gadzinski A.J. et al. Long-term outcomes of immediate versus delayed nephroureterectomy for upper tract urothelial carcinoma. J Endourol 2012;26:566.
Lee J.N. et al. Impact of surgical wait time on oncologic outcomes in upper urinary tract urothelial carcinoma. J Surg Oncol 2014;110:468.
Waldert M. et al. A delay in radical nephroureterectomy can lead to upstaging. BJU Int 2010;105:812.
Favaretto R.L. et al. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World J Urol 2017;35:113.
Scarpini S. et al. Impact of the expression of Aurora-A, p53, and MIB-1 on the prognosis of urothelial carcinomas of the upper urinary tract. Urol Oncol 2012;30:182.
Roupret M. et al. Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. Urology 2005;65:1233.
Krabbe L.M. et al. Prognostic value of PD-1 and PD-L1 expression in patients with high grade upper tract urothelial carcinoma. J Urol 2017;198:1253.
Seisen T. et al. A systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma. Eur Urol 2015;67:1122.
Seisen T. et al. Oncologic outcomes of kidney-sparing surgery versus radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the EAU Nonmuscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 2016;70:1052.
Leow J.J. et al. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 2014;66:529.
Cutress M.L. et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 2012;110:614.
Cornu J.N. et al. Oncologic control obtained after exclusive flexible ureteroscopic management of upper urinary tract urothelial cell carcinoma. World J Urol 2010;28:151.
Jeldres C. et al. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010;183:1324.
Colin P. et al. Comparison of oncological outcomes after segmental ureterectomy or radical nephroureterectomy in urothelial carcinomas of the upper urinary tract: results from a large French multicentre study. BJU Int 2012;110:1134.
Lopez-Beltran A. et al. Tumours of the urinary system. In: World Health Organization classification of tumors: pathology and genetics of tumours of the urinary system and male genital organs. Eds.: Eble J.N. et al. Lyon: IARC Press, 2004.
Irie A. et al. Intravesical instillation of bacille Calmette–Guerin for carcinoma in situ of the urothelium involving the upper urinary tract using vesicoureteral reflux created by a double- pigtail catheter. Urology 2002;59:53.
Horiguchi H. et al. Impact of bacillus Calmette–Guerin therapy of upper urinary tract carcinoma in situ: comparison of oncological outcomes with radical nephroureterectomy. Med Oncol 2018;35:41.
Tomisaki I. et al. Efficacy and tolerability of bacillus Calmette–Guerin therapy as the first-line therapy for upper urinary tract carcinoma in situ. Cancer Invest 2018;36:152.
Yossepowitch O. et al. Assessment of vesicoureteral reflux in patients with self-retaining ureteral stents: implications for upper urinary tract instillation. J Urol 2005;173:890.
Ong A.M. et al. Trocar site recurrence after laparoscopic nephroureterectomy. J Urol 2003;170:1301.
Ni S. et al. Laparoscopic versus open nephroureterectomy for the treatment of upper urinary tract urothelial carcinoma: a systematic review and cumulative analysis of comparative studies. Eur Urol 2012;61:1142.
Ariane M.M. et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012;19:301.
Simone G. et al. Laparoscopic versus open nephroureterectomy: perioperative and oncologic outcomes from a randomized prospective study. Eur Urol 2009;56:520.
Adibi M. et al. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol 2012;19:1060.
Clements M.B. et al. Robotic-assisted surgery for upper tract urothelial carcinoma: a comparative survival analysis. Ann Surg Oncol 2018;25:2550.
Rodriguez J.F. et al. Utilization and outcomes of nephroureterectomy for upper tract urothelial carcinoma by surgical approach. J Endourol 2017;31:661.
Aboumohamed A.A., et al. Oncologic outcomes following robot-assisted laparoscopic nephroureterectomy with bladder cuff excision for upper tract urothelial carcinoma. J Urol 2015;194:1561.
Moschini M. et al. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. World J Urol 2017;35:1541.
Zareba P. et al. Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer 2017;123:1741.
Dominguez-Escrig J.L. et al. Potential benefit of lymph node dissection during radical nephroureterectomy for upper tract urothelial carcinoma: a systematic review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer. Eur Urol Focus 2019:5:224.
Giannarini G. et al. Antegrade perfusion with bacillus Calmette–Guerin in patients with non- muscle-invasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol 2011;60:955.
Herr H.W. Extravesical tumor relapse in patients with superficial bladder tumors. J Clin Oncol 1998;16:1099.
Matin S.F. et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 2010;116:3127.
Liao R.S. et al. Comparison of pathological stage in patients treated with and without neoadjuvant chemotherapy for high risk upper tract urothelial carcinoma. J Urol 2018;200:68.
Porten S. et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 2014;120:1794.
Kubota Y. et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget 2017;8:101500.
Moschini M. et al. Impact of primary tumor location on survival from the European Organization For The Research And Treatment Of Cancer Advanced Urothelial Cancer Studies. J Urol 2018;199:1149.
Balar A.V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 2017;18:1483.
Balar A.V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 2017;389:67.
Heers H. et al. Vinflunine in the treatment of upper tract urothelial carcinoma – subgroup analysis of an observational study. Anticancer Res 2017;37:6437.
Rosenberg J.E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a singlearm, multicentre, phase 2 trial. Lancet 2016;387:1909.
Powles T. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomized controlled trial. Lancet 2018;391:748.
Goldberg H. et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget 2018;9:18797.
Necchi A. et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 2018;121:252.
Fujita K. et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol 2017;17:110.
Birtle A.J. et al. Results of POUT: A phase III randomized trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol 2018;36:407.
Faltas B.M. et al. Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes. Urol Oncol 2018;36:9.e11.
Ploussard G. et al. Conditional survival after radical nephroureterectomy for upper tract carcinoma. Eur Urol 2015;67:803.
Shigeta K. et al. The conditional survival with time of intravesical recurrence of upper tract urothelial carcinoma. J Urol 2017;198:1278.
Sudakoff, G.S., et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol, 2008. 179: 862.
Wang, L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524.
Wang, L.J., et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol, 2010. 183: 48.
Jinzaki, M., et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol, 2011. 196: 1102.
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. Kamat AM1, Bellmunt J2, Galsky MD J Immunother Cancer. 2017 Aug 15;5(1):68. doi: 10.1186/s40425-017-0271-0.
Czito, B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172(4 Pt 1):1271.https://www.ncbi.nlm.nih.gov/pubmed/15371822
Rev Urol. 2006 Spring; 8(2): 61–70.Treatment of Upper Tract Urothelial Carcinoma: A Review of Surgical and Adjuvant Therapy Kalyan C Latchamsetty, MD and Christopher R Porter, MDCancer Med. 2018 Dec; 7(12): 6112–6123. Validation of the preoperative controlling nutritional status score as an independent predictor in a large Chinese cohort of patients with upper tract urothelial carcinoma Hang Xu, 1 Ping Tan, 1 Xi Jin.
Gopalakrishna A , Longo TA , Fantony JJ , et al . Lifestyle factors and health-related quality of life in bladder Cancer survivors: a systematic review. J Cancer Surviv 2016;10:874– 82.doi:10.1007/s11764-016-0533-8
Maloney, I., Parker, D. C., Cookson, M. S., & Patel, S. (2017). Bladder Cancer Recovery Pathways: A Systematic Review. Bladder cancer (Amsterdam, Netherlands), 3(4), 269–281.
Silverdale N, Wherry M, Roodhouse A. Massage and reflexology for post-operative cancer cystectomy patients: Evaluation of a pilot service. Complement Ther Clin Pract. 2019 Feb;34:109-112.
49 Stout NL, Baima J, Swisher AK, Winters-Stone KM, Welsh J. A Systematic Review of Exercise Systematic Reviews in the Cancer Literature (2005-2017). PM R. 2017 Sep;9(9S2):S347-S384.
Kinkead B, Schettler PJ, Larson ER, Carroll D, Sharenko M, Nettles J, Edwards SA, Miller AH1, Torres MA, Dunlop BW, Rakofsky JJ, Rapaport MH. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial. Cancer. 2018 Feb 1;124(3):546-554.
Streckmann F, Zopf EM, Lehmann HC, et al: Exercise intervention studies in patients with peripheral neuropathy: a systematic review. Sports Med 2014;44:1289-1304
Kleckner IR, Kamen C, Gewandter JS, et al: Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019-1028.
Muzi JL, Look RM., Turner C, Gardiner SK, Wagie T, Douglas J, Sorenson L, Evans L, Kirchner S, Dashkoff C, Garrett K, Johnson N. Low-level laser therapy for chemotherapy-induced peripheral neuropathy. Journal of Clinical Oncology 30, no. 15_suppl (May 2012) 9019-9019.
54 Rick, O., von Hehn, U., Mikus, E., Dertinger, H., & Geiger, G. (2016). Magnetic field therapy in patients with cytostatics-induced polyneuropathy: A prospective randomized placebo- controlled phase-III study. Bioelectromagnetics, 38(2), 85-94.
Kılınç M, Livanelioğlu A, Yıldırım SA, Tan E. Effects of transcutaneous electrical nerve stimulation in patients with peripheral and central neuropathic pain. J Rehabil Med. 2014 May;46(5):454-60. doi: 10.2340/16501977-1271.
Oberoi S, Zamperlini-Netto G, Beyene J, Treister NS, Sung L. Effect of prophylactic low level laser therapy on oral mucositis: a systematic review and meta-analysis. Send to PLoS One. 2014 Sep 8;9(9):e107418.
Ross M, Fischer-Cartlidge E. Scalp Cooling: A Literature Review of Efficacy, Safety, and Tolerability for Chemotherapy-Induced Alopecia. Clin J Oncol Nurs. 2017 Apr 1;21(2):226-233. doi: 10.1188/17.CJON.226-233
Visser, Wilhelmina S et al. Pelvic floor rehabilitation to improve functional outcome after a low anterior resection: a systematic review. Annals of coloproctology vol. 30,3 (2014): 109-14.
Avci, P., Gupta, G. K., Clark, J., Wikonkal, N., & Hamblin, M. R. (2013). Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers in surgery and medicine, 46(2), 144-51.
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2019 Update [Электронный источник]// European Association of Urology [сайт]. URL: https://uroweb.org/guideline/upper-urinary-tract-urothelial-cell-carcinoma/ (дата обращения: 20.11.2019).
Redrow, G.P., et al. Upper Urinary Tract Carcinoma In Situ: Current Knowledge, Future Direction. J Urol, 2017. 197: 287.
Giannarini, G., et al. Antegrade perfusion with bacillus Calmette-Guerin in patients with non- muscleinvasive urothelial carcinoma of the upper urinary tract: who may benefit? Eur Urol, 2011. 60: 955.
Pollard ME, Levinson AW, Shapiro EY, et al: Comparison of 3 Upper Tract
Anticarcinogenic Agent Delivery Techniques in an Ex Vivo Porcine Model. Urology 2013; 82: 1451. e1–1451. e6.
Roupret M, Babjuk M, Comperat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol 2018;73:111-122. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28867446.
Mandalapu RS, Remzi M, de Reijke TM, et al. Update of the ICUD- SIU consultation on upper tract urothelial carcinoma 2016: treatment of low-risk upper tract urothelial carcinoma. World J Urol 2017;35:355-365. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27233780.
O"Brien T, Ray E, Singh R, et al. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). Eur Urol 2011;60:703-710. Available at: https://www.ncbi.nlm.nih.gov/pubmed/21684068.
Ito A, Shintaku I, Satoh M, et al. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial. J Clin Oncol 2013;31:1422-1427. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23460707.
Miyamoto K, Ito A, Wakabayashi M, et al. A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III). Jpn J Clin Oncol 2018;48:94- 97. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29136187.
Kim DK, Lee JY, Kim JW, et al. Effect of neoadjuvant chemotherapy on locally advanced upper tract urothelial carcinoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol 2019;135:59-65. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30819447.
Audenet, F., et al. The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol, 2013. 31: 407.
Kaag, M.G., et al. Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol, 2010. 58: 581. https://www.ncbi.nlm.nih.gov/pubmed/20619530
Lane, B.R., et al. Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer, 2010. 116: 2967. https://www.ncbi.nlm.nih.gov/pubmed/20564402
Goldberg, H., et al. Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis. Oncotarget, 2018. 9: 18797. https://www.ncbi.nlm.nih.gov/pubmed/29721162.
Necchi, A., et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. BJU Int, 2018. 121: 252. https://www.ncbi.nlm.nih.gov/pubmed/28940605
Fujita, K., et al. Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis. BMC Urol, 2017. 17: 110. https://www.ncbi.nlm.nih.gov/pubmed/29195499
Seisen, T., et al. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol, 2017. 35: 852. https://www.ncbi.nlm.nih.gov/pubmed/28045620].
Birtle, A.J., et al. Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC). J Clin Oncol, 2018. 36: 407. http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.6_suppl.407
Нahn, A.W., et al. Effect of Adjuvant Radiotherapy on Survival in Patients with Locoregional Urothelial Malignancies of the Upper Urinary Tract. Anticancer Res, 2016. 36: 4051.https://www.ncbi.nlm.nih.gov/pubmed/27466512
Huang, Y.C., et al. Adjuvant radiotherapy for locally advanced upper tract urothelial carcinoma. Sci Rep, 2016. 6: 38175. https://www.ncbi.nlm.nih.gov/pubmed/27910890
.Czito, B., et al. Adjuvant radiotherapy with and without concurrent chemotherapy for locally advanced transitional cell carcinoma of the renal pelvis and ureter. J Urol, 2004. 172(4 Pt 1):1271. https://www.ncbi.nlm.nih.gov/pubmed/15371822
Shigeta, K., et al. The Conditional Survival with Time of Intravesical Recurrence of Upper Tract Urothelial Carcinoma. J Urol, 2017. 198: 1278.https://www.ncbi.nlm.nih.gov/pubmed/28634017
Bellmunt J. et al. New therapeutic challenges in advanced bladder cancer. Semin Oncol 2012. 39: 598.
Sternberg C.N. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 2001. 19: 2638.
Galsky M.D. et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin- based chemotherapy. J Clin Oncol 2011. 29: 2432.
De Santis M. et al. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. J Clin Oncol 2009. 27: 5634.
Sudakoff, G.S., et al. Multidetector computerized tomography urography as the primary imaging modality for detecting urinary tract neoplasms in patients with asymptomatic hematuria. J Urol, 2008. 179: 862.https://www.ncbi.nlm.nih.gov/pubmed/18221955
Wang, L.J., et al. Diagnostic accuracy of transitional cell carcinoma on multidetector computerized tomography urography in patients with gross hematuria. J Urol, 2009. 181: 524. https://www.ncbi.nlm.nih.gov/pubmed/19100576
Wang, L.J., et al. Multidetector computerized tomography urography is more accurate than excretory urography for diagnosing transitional cell carcinoma of the upper urinary tract in adults with hematuria. J Urol, 2010. 183: 48. https://www.ncbi.nlm.nih.gov/pubmed/19913253
Jinzaki, M., et al. Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. AJR Am J Roentgenol, 2011. 196: 1102. https://www.ncbi.nlm.nih.gov/pubmed/21512076
Rosenthal DL, et al. The Paris System for Reporting Urinary Cytology. 2016, Switzerland 2016.
Chen, A.A., et al. Is there a role for FISH in the management and surveillance of patients with upper tract transitional-cell carcinoma? J Endourol, 2008. 22: 1371. https://www.ncbi.nlm.nih.gov/pubmed/18578665
Johannes, J.R., et al. Voided urine fluorescence in situ hybridization testing for upper tract urothelial carcinoma surveillance. J Urol, 2010. 184: 879. https://www.ncbi.nlm.nih.gov/pubmed/20643443
Cowan, N.C., et al. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int, 2007. 99: 1363.https://www.ncbi.nlm.nih.gov/pubmed/17428251
Lee, K.S., et al. MR urography versus retrograde pyelography/ureteroscopy for the exclusion of upper urinary tract malignancy. Clin Radiol, 2010. 65: 185. https://www.ncbi.nlm.nih.gov/pubmed/20152273
Cutress, M.L., et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int, 2012. 110: 614. https://www.ncbi.nlm.nih.gov/pubmed/22471401
Roupret, M., et al. Upper urinary tract transitional cell carcinoma: recurrence rate after percutaneous endoscopic resection. Eur Urol, 2007. 51: 709. https://www.ncbi.nlm.nih.gov/pubmed/16911852
Song, Y. S., Cho, J. S., Cho, K. S., Doo, S. H., Chung, B. H., Kim, S. J., … Hong, S. J. (2010). Efficacy of Adjuvant Gemcitabine-Cisplatin Chemotherapy: A Comparative Study between Locally Advanced Transitional Cell Carcinoma of the Bladder and Upper Urinary Tract. Urologia Internationalis, 85(1), 47–51. doi:10.1159/000296294
Bellmunt, J., de Wit, R., Albanell, J., & Baselga, J. (2001). A feasibility study of carboplatin with fixed dose of gemcitabine in “unfit” patients with advanced bladder cancer. European Journal of Cancer, 37(17), 2212–2215. doi:10.1016/s0959-8049(01)00295-7
https://rosoncoweb.ru/standarts/RUSSCO/2015/28.pdf
Bellmunt J, de Wit R, Vaughn DJ, et al. on behalf of the keynote-045 investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015–26. doi: 10.1056/NEJMoa1613683.
Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–22. doi: 10.1016/S1470-2045(17)30065-7.
Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum- based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20. doi: 10.1016/S0140-6736(16)00561-4.
Приказ от 24 марта 2016 г. № 179н министерства здравоохранения Российской Федерации О Правилах проведения патолого-анатомических исследований http://pravo.gov.ru/proxy/ips/?doc_itself=&backlink=1&nd=102396069&page=1&rdk=0#I0
Приказ от 10 мая 2017 г. N 203н министерства здравоохранения Российской Федерации Об утверждении критериев оценки качества медицинской помощи.
Для продолжения работы требуется
Registration
Предыдущая страница
Следующая страница
Table of contents
Список сокращений
Термины и определения
Уротелиальный рак верхних мочевыводящих путей
+
Список литературы
Приложение А1. Состав рабочей группы
Приложение А2. Методология разработки клинических рекомендаций
Приложение А3. Связанные документы
Приложение Б. Алгоритмы ведения пациента
Приложение В. Информация для пациентов
Приложение Г.
+
Данный блок поддерживает скрол*